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GABAB receptor subtypes are based on the subunit isoforms GABAB1a and GABAB1b , which associate with GABAB2 subunits to form
pharmacologically indistinguishable GABAB(1a,2) and GABAB(1b,2) receptors. Studies with mice selectively expressing GABAB1a or
GABAB1b subunits revealed that GABAB(1a,2) receptors are more abundant than GABAB(1b,2) receptors at glutamatergic terminals. Ac-
cordingly, it was found that GABAB(1a,2) receptors are more efficient than GABAB(1b,2) receptors in inhibiting glutamate release when
maximally activated by exogenous application of the agonist baclofen. Here, we used a combination of genetic, ultrastructural and
electrophysiological approaches to analyze towhat extent GABAB(1a,2) andGABAB(1b,2) receptors inhibit glutamate release in response to
physiological activation. We first show that at hippocampal mossy fiber (MF)-CA3 pyramidal neuron synapses more GABAB1a than
GABAB1b protein is present at presynaptic sites, consistent with the findings at other glutamatergic synapses. In the presence of baclofen
at concentrations1M,bothGABAB(1a,2) andGABAB(1b,2) receptors contribute topresynaptic inhibitionof glutamate release.However,
at lower concentrations of baclofen, selectively GABAB(1a,2) receptors contribute to presynaptic inhibition. Remarkably, exclusively
GABAB(1a,2) receptors inhibit glutamate release in response to synaptically released GABA. Specifically, we demonstrate that selectively
GABAB(1a,2) receptors mediate heterosynaptic depression of MF transmission, a physiological phenomenon involving transsynaptic
inhibition of glutamate release via presynaptic GABAB receptors. Our data demonstrate that the difference in GABAB1a and GABAB1b
protein levels atMF terminals is sufficient to produce a strictly GABAB1a-specific effect under physiological conditions. This consolidates
that the differential subcellular localization of the GABAB1a and GABAB1b proteins is of regulatory relevance.
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Introduction
GABAB receptors are the G-protein coupled receptors for
-aminobutyric acid (GABA), the main inhibitory neurotrans-
mitter in the CNS. They have been implicated in a variety of
disorders, including cognitive impairments, anxiety, depression
and epilepsy (Calver et al., 2002; Bettler et al., 2004). Presynaptic
GABAB receptors inhibit neurotransmitter release via the inhibi-
tion of Ca2 channels and second-messenger-mediated effects
downstream of Ca2 entry (Scanziani et al., 1992; Jarolimek and
Misgeld, 1997; Yamada et al., 1999; Sakaba and Neher, 2003).
They are commonly divided into autoreceptors and heterorecep-
tors depending on whether they control the release of GABA or
other neurotransmitters, respectively. Postsynaptic GABAB re-
ceptors activate Kir3-type K channels, which induces slow in-
hibitory potentials and mediates shunting inhibition (Lu¨scher et
al., 1997). The physiological functions of GABAB receptors have
been mostly inferred from electrophysiological experiments in
which the receptors were pharmacologically activated by exoge-
nous application of the agonist baclofen. Physiological activation
of GABAB receptors usually requires strong stimulus intensities,
suggesting that pooling of synaptically released GABA is required
to activate them (Isaacson et al., 1993; Scanziani, 2000). This
agrees with ultrastructural data demonstrating that most GABAB
receptors are located distant from release sites (Lo´pez-Bendito et
al., 2004; Lacey et al., 2005; Kulik et al., 2006). A tonic activation
of GABAB receptors through ambient GABA was also observed,
which may partly explain their predominantly extrasynaptic lo-
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calization as well (Lei and McBain, 2003; Price et al., 2005; Liu et
al., 2006).
GABAB receptors are heteromers composed of GABAB1 and
GABAB2 subunits (Calver et al., 2002; Bettler et al., 2004). The
onlymolecular distinction in theGABAB receptor system is based
on the subunit isoforms GABAB1a and GABAB1b, which differ in
their ectodomains by a pair of “sushi domains” that are unique to
GABAB1a (Hawrot et al., 1998). Heteromeric GABAB(1a,2) and
GABAB(1b,2) receptors do not exhibit pharmacological differ-
ences and couple to the same effector systems in transfected cells.
To address the reason for the existence of two receptor subtypes
we generated GABAB1a
/ (1a/) and GABAB1b
/ (1b/)
mice, which express either one or the other GABAB1 subunit
isoform. Pharmacological studies with these mice suggest that
GABAB1a and GABAB1b differentially influence synaptic func-
tions, primarily as a result of their distinct distributions to axonal
and dendritic compartments (Ulrich and Bettler, 2007). In prin-
ciple, since GABAB1a and GABAB1b subunits are independently
regulated at the transcriptional level (Steiger et al., 2004), this
allows for dynamically adjustable GABAB signaling at axonal and
dendritic effectors. However, to clearly establish a regulatory sig-
nificance for GABAB receptor subtypes, it needs to be demon-
strated that they not only yield differential effects in response to
pharmacological activation, but also in response to physiological
activation (Huang, 2006). A physiological phenomenon pro-
posed to rely on the endogenous activation of GABAB heterore-
ceptors is heterosynaptic depression (Isaacson et al., 1993; Vogt
and Nicoll, 1999; Chandler et al., 2003). Here, we studied het-
erosynaptic depression atMF-CA3pyramidal neuron synapses to
address to what extent the two GABAB receptor subtypes inhibit
glutamate release in response to activation by synaptically re-
leased GABA.
Materials andMethods
Mutant mouse strains. The generation of 1a/ and 1b/ mice was
described previously (Vigot et al., 2006). For control experiments we
additionally used GABAB1-deficient (1
/) mice that completely lack
GABAB1 protein (Schuler et al., 2001). Homozygous mutant mice and
wild-type (WT) littermatemice were obtained by breeding heterozygous
mice on a pure inbred BALB/c genetic background. All animal experi-
ments were subjected to institutional review and approved by the veter-
inary office of Basel-Stadt.
Pre-embedding immunocytochemistry and quantitative analysis. Pre-
embedding GABAB1 immunogold labeling and electron microscopy was
done as described, using affinity-purified guinea pig polyclonal anti-
serum B62 raised against the C-terminal 103 amino acid residues of
GABAB1a and GABAB1b (Kulik et al., 2006). Light microscopy confirmed
that the B62 antiserum immunostains WT, 1a/, and 1b/ hip-
pocampal sections, but not 1/ sections (data not shown). Pre-
embedding electronmicroscopy showed a reduction of the immunogold
particle density by 86% in 1/ hippocampal sections compared with
WT sections, which agrees well with earlier control experiments where
the reduction of immunogold particles in 1/ sections was 88% (Vigot
et al., 2006). Immunogold particles that nonspecifically labeled 1/
sections were approximately equally distributed over presynaptic and
postsynaptic membranes, as described (Vigot et al., 2006). Pre-
embedding electron microscopy of WT, 1a/, and 1b/ mice (8–12
weeks old, n 3 per genotype) included the analysis of 10 different MF
boutons per mouse. MF boutons were identified by their large size (3–6
m in diameter), the dense packing with synaptic vesicles and their
contacts with at least 2 spines. For each MF bouton we examined at least
4 consecutive sections. Only immunogold particles at the plasma mem-
brane (closer than 20 nm) of morphologically identifiable largeMF bou-
tons and their postsynaptic structures were analyzed. The postsynaptic
distribution of GABAB1 protein relative to asymmetrical, putative gluta-
matergic synapses was determined by measuring the distance between
each immunogold particle and the edge of the nearest synapse along the
surface of spines. Immunogold particles were allocated to 60 nm wide
bins, followed by calculating the relative abundance in each bin. The
experimenter was blind to the genotype of the mice.
Immunoblot quantification. The ratio of GABAB1a to GABAB1b protein
in the CA3 region of the hippocampus was determined by immunoblot
analysis using rabbit polyclonal GABAB1 antiserum Ab174.1 raised
against the C-terminal domain of GABAB1a and GABAB1b (Vigot et al.,
2006). Scanned immunoblots were quantified using Scion Image soft-
ware (Scion).
Slice preparation and electrophysiology. Hippocampal slices were pre-
pared from 21- to 35-d-old mice using standard procedures (Vigot et al.,
2006). Parasagittal slices (300 m thick) were cut in ice-cold artificial
CSF (ACSF) containing (in mM) 124 NaCl, 2.7 KCl, 1.3 MgCl2, 2 CaCl2,
1.24 NaH2PO4, 26 NaHCO3, 18 glucose, 2.25 ascorbate, pH 7.3, equili-
brated with 95% O2/5% CO2. Slices were kept in oxygenated ACSF at
35°C for at least 45 min before recording. Visualized whole-cell patch-
clamp recording was used to investigate presynaptic and postsynaptic
GABAB receptor functions. Holding currents and excitatory synaptic
responses were recorded at 3032°C from the somata of CA3 pyramidal
neurons visualized using an infrared-sensitive camera (Till Photonics)
and differential interference contrast optics (BX51WI; Olympus). Drugs
were applied by superfusion into the recording chamber.
EPSCs were recorded with electrodes (5 M) filled with a solution
containing (inmM): 140 Cs-gluconate, 10HEPES, 10 phosphocreatine, 5
QX-314, 4 Mg-ATP, 0.3 Na-GTP, at pH 7.25 with CsOH, 285 mOsm.
EPSCs were elicited by voltage pulses (100 s, 2–5 V stimuli) delivered
through a bipolar Pt-Ir electrode (25 m in diameter) placed in the
stratum lucidum. MF EPSCs were identified by the presence of a
frequency-dependent short-term facilitation. EPSCs were measured at
70 mV in the presence of 100 M picrotoxin. Presynaptic GABAB and
adenosine receptors were activated by bath application of baclofen (50
M) and adenosine (100M), respectively. GABAB receptors were inhib-
ited by application of the antagonist CGP54626A (1M). For the presyn-
aptic dose–response experiments, baclofen at different concentrations
(0.1, 1 and 50 M) was bath applied for 5 min at 10 min intervals.
To record postsynaptic Kir3-type K currents, patch pipettes were
filled with a solution containing (in mM): 140 K-gluconate, 5 HEPES, 2
MgCl2, 1.1 EGTA, 2 Na2-ATP, 5 phosphocreatine, 0.6 Tris-GTP, at pH
7.25 with KOH, 285 mOsm. Kir3-type K currents induced by baclofen
(100M) or adenosine (100M) were elicited at50mV in the presence
of tetrodotoxin (TTX, 1 M). For concentration-response experiments
we applied baclofen solutions (0.3 – 100 M) for 30 s using the fast
gravitation driven application systemWAS-02 (Dittert et al., 2006). The
inner diameter of the application tubewas 300m.The distance between
the mouth of the tube and the soma of the neuron was 400 m.
GABAA- andGABAB-mediated IPSCs (early and late IPSCs, respectively)
were recorded with a solution containing (in mM) 124 K-gluconate, 16
KCl, 5HEPES, 2MgCl2, 1.1 EGTA, 2MgATP, 3Na3GTP, pH 7.25. IPSCs
were elicited at 60 mV by 100 s pulses (3 stimuli at 100 Hz) in the
presence of kynurenic acid (2 mM), DNQX (10 M), naloxone (10 M)
and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 1 M) to block gluta-
mate, opioid and A1 adenosine receptors.
GABAB-mediated heterosynaptic depression atMF synapses was stud-
ied by recording field EPSPs (fEPSPs) in the stratum lucidum (Vogt and
Nicoll, 1999; Chandler et al., 2003). The occurrence of heterosynaptic
depression is not critically dependent on the temperature, as no signifi-
cant differences were previously observed between experiments at room
temperature and at 34°–36°C (Vogt and Nicoll, 1999). We therefore
recorded fEPSPs at room temperature, using low resistance glass pipettes
filled with ACSF. Stimulating electrodes filled with ACSF were posi-
tioned into the dentate gyrus, andMF responses elicited by 100s pulses.
MF-evoked fEPSPs were identified through their characteristic short-
term plasticity and their sensitivity to the group II mGluR agonist
(2S,2R,3R)-2-(2,3-dicarboxycyclopropyl)-glycine (DCG-IV, 2 M)
(Kamiya et al., 1996). Heterosynaptic depression was measured in the
presence of naloxone (10 M) and DPCPX (1 M) to avoid interference
frompresynaptic opioid andA1 adenosine receptors, respectively (Weis-
skopf et al., 1993; Manzoni et al., 1994; Cunha, 2008). Under these con-
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ditions heterosynaptic depression was significantly reduced by the
GABAB antagonist CGP54626A (2M).Datawere acquiredwith anAxo-
patch 200B (Molecular Devices), filtered at 2 kHz and digitized at 10 kHz
using a Digidata 1322A Interface (Molecular Devices) driven by pClamp
9.2 software (Molecular Devices). Whole-cell currents and field poten-
tials were analyzed using Clampfit 9.2 software (Molecular Devices).
Baclofen and CGP54626A were from Novartis Pharma. Naloxone,
DNQX, DPCPX, and DCG-IV were from Tocris Cookson, TTX from
Latoxan. All other reagents were from Sigma-Aldrich. Most recordings
were made and analyzed in blind. All values are means SEM.
Results
Presynaptic versus postsynaptic distribution of GABAB1
isoforms at MF-CA3 pyramidal neuron synapses
Before addressing the contribution of GABAB receptor subtypes
to presynaptic inhibition at MF terminals, we determined the
GABAB1a and GABAB1b distribution at presynaptic and postsyn-
aptic sites. We performed pre-embedding immunogold electron
microscopy in the hippocampal CA3 stratum lucidum of WT,
1a/, and 1b/mice, using a pan GABAB1 antibody recogniz-
ingGABAB1a andGABAB1b.MF-CA3pyramidal neuron synapses
within large MF boutons were identified at the ultrastructural
level as asymmetrical synapses at the spines of pyramidal neu-
rons. InWTmiceGABAB1 proteinwas present at presynaptic and
postsynaptic elements of MF-CA3 pyramidal neuron synapses
(Fig. 1A–C). 19.3 10.7% of all counted immunogold particles
were localized at synaptic and extrasynaptic sites of MF boutons,
while the remaining 80.7  10.7% were associated with spines
and proximal dendritic shafts of pyramidal neurons (Fig. 1 J). A
similar distribution was reported for the MF-CA3 pyramidal
neuron synapse in rat brain (Kulik et al., 2003). In 1a/ mice,
92.7 2.1%of all immunogold particles were observed on spines
and dendritic shafts of pyramidal neurons, indicating that
GABAB1b protein mainly localizes to postsynaptic elements (Fig.
1D–F, J). In contrast, in 1b/ mice 55.3  4.6% of all immu-
nogold particles were associated with the presynaptic membrane
of MF boutons, demonstrating that GABAB1a protein is slightly
more abundant at presynaptic elements (Fig. 1G–J). Strikingly,
the ratios of pre- to postsynaptic immunogold particles in the
different genotypes were similar at MF-CA3 pyramidal neuron
synapses (ratios for WT: 0.24, 1a/: 0.08, 1b/: 1.24) and
CA3-CA1 synapses (ratios for WT: 0.31, 1a/: 0.17, 1b/:
1.61; (Vigot et al., 2006)). Quantification from immunoblots in-
dicates an overall GABAB1a to GABAB1b protein ratio of 0.60 
0.04 (n 4mice, p 0.01, one sample Student’s t test) in theCA3
region of the hippocampus (data not shown). Considering this
ratio and the synaptic distribution of immunogold particles, we
approximately estimate that the GABAB1a to GABAB1b protein
ratio at presynaptic and postsynaptic sites is 4.5:1 and 1:3.5, re-
spectively. Importantly, we did not observe any MF boutons and
associated postsynaptic spines without specific immunogold par-
ticle labeling, suggesting thatmost, if not all,MF synapses express
GABAB receptors.
Subsynaptic distribution of GABAB1 isoforms in presynaptic
and postsynaptic elements of MF-CA3 pyramidal neuron
synapses
We next studied the distribution of GABAB1 protein relative to
synaptic specializations at MF-CA3 pyramidal neuron synapses.
We first determined the percentage ofGABAB1 immunogold par-
ticles in MF boutons that are present at presynaptic membranes
opposite to postsynaptic densities (PSDs). In WT and 1b/
mice 22% of all presynaptic GABAB1 immunogold particles were
localized opposite to PSDs and 78% at extrasynaptic membranes
(Fig. 2A). In 1a/mice 11% of all immunogold particles in MF
boutons were found opposite to PSDs, demonstrating that the
GABAB1b protein distribution is significantly shifted toward ex-
trasynaptic sites. Considering an overall GABAB1a to GABAB1b
protein ratio of 0.60 (see above), we approximately estimate a
GABAB1a to GABAB1b protein ratio of 9:1 in the active zones of
MF boutons. We additionally analyzed the distribution of
GABAB1 protein in dendritic spines of CA3 pyramidal neurons.
Independent of the genotype we rarely observed immunogold
particles in the PSD, likely because the pre-embedding technique
limits penetration of immunoreagents into the PSD (Kulik et al.,
2002, 2003). However, we did not observe any significant differ-
ences betweenWT, 1a/, and 1b/mice in the distribution of
GABAB1 immunoparticles at perisynaptic and extrasynaptic den-
dritic sites (Fig. 2B). Of note,20% of all immunoparticles were
found within 60 nm from the edge of the PSDs at perisynaptic
sites.
GABAB(1a,2) receptors are more efficient than GABAB(1b,2)
receptors in inhibiting glutamate release in response to
pharmacological activation
We used whole-cell patch-clamp recording in slice preparations
from WT, 1a/, and 1b/ mice to examine to what extent
GABAB(1a,2) and GABAB(1b,2) receptors can inhibit glutamate re-
lease in response to a maximally active concentration of the ago-
nist baclofen. Stimulation ofMFs in the stratum lucidum induces
EPSCs in CA3 pyramidal neurons that are reduced in amplitude
by activation of GABAB heteroreceptors. A high concentration of
baclofen (50M) reduced EPSC amplitudes in all three genotypes
(Fig. 3A,B). However, baclofen was significantly less effective in
inhibiting release in 1a/mice than inWT and 1b/mice. As
a control, activation of adenosine A1 receptors by adenosine in-
hibited glutamate release in all three genotypes to a similar extent
(Fig. 3A,B). We tested whether lower concentrations of baclofen
(0.1, 1 M) activate GABAB(1a,2) heteroreceptors without engag-
ingGABAB(1b,2) heteroreceptors (Fig. 3C). This was the case at 0.1
M, at which concentration baclofen reduced glutamate release
in WT and 1b/ mice but not in 1a/ mice (Fig. 3C). Alto-
gether, the electrophysiological data therefore parallel the ultra-
structural data described above (Figs. 1, 2). They support that the
number of GABAB(1a,2) heteroreceptors in 1b
/ mice is suffi-
cient to produce a maximal level of presynaptic inhibition (sim-
ilar toWT), while GABAB(1b,2) heteroreceptors in 1a
/mice are
limiting and consequently produce submaximal inhibition. At
low concentrations of baclofen, onlyGABAB(1a,2) heteroreceptors
appear to be present in sufficient numbers to inhibit glutamate
release.
Recent reports show that certain presynaptic GABAB recep-
tors can be tonically activated by ambient GABA (Jensen et al.,
2003; Lei andMcBain, 2003; Liu et al., 2006). Bath application of
the GABAB antagonist CGP54626A had no effect on the ampli-
tudes of evoked EPSCs in WT, 1a/, and 1b/ mice (Fig.
3D,E). This demonstrates that under our experimental condi-
tions ambient GABA does not tonically activate GABAB hetero-
receptors at MF boutons.
GABAB(1a,2) and GABAB(1b,2) receptors activate postsynaptic
K channels to a similar extent in response to
pharmacological activation
We next studied the relative contributions of GABAB1a and
GABAB1b isoforms to the formation of functional somatoden-
dritic GABAB receptors on CA3 pyramidal neurons, using so-
matic whole-cell patch-clamp recordings in slices. Somatoden-
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driticGABAB receptors induce a late IPSCby activatingKir3-type
K channels (Lu¨scher et al., 1997). At a holding potential of50
mV and at a physiological concentration of extracellular K,
pharmacological activation with a maximally active concentra-
tion of baclofen (100M) elicited smaller outwardK currents in
CA3 pyramidal cells of 1a/ and 1b/ mice compared with
WT mice (Fig. 4A,B). The maximal K currents induced by
baclofen were similar in 1a/ and 1b/ mice, thus showing
that GABAB(1b,2) and GABAB(1a,2) receptors activate K
 channels
to a similar extent. Pharmacological activation of adenosine A1
receptors, which converge on the same Kir3-type K channels
(Lu¨scher et al., 1997), induced similar outward currents in all
genotypes (Fig. 4A,B). This indicates that the expression levels of
4
the edge of the presynaptic membrane specialization and at perisynaptic and extrasynaptic
dendritic sites. D–F, In 1a/ mice, immunogold particles were almost exclusively found in
postsynaptic elements, predominantly at perisynaptic and extrasynaptic sites. In rare cases,
immunogoldparticleswerealsoobserved inMFboutons (E).G–I, In 1b/mice, immunogold
particles were observed in presynaptic and postsynaptic elements. Immunogold particles were
frequently found at the presynaptic membrane specialization of MF boutons. J, Quantitative
analysis of presynaptic versus postsynaptic immunogold particles in WT, 1a/, and 1b/
mice (percentage presynaptic particles: WT, 19.3 10.7%; 1a/, 7.3 2.1%; 1b/,
55.3 4.6%; n 3 mice per genotype). Immunogold particles were less frequent in 1b/
compared with 1a/ and WT mice, which is reflected by the total number of particles that
were analyzed (WT: n 1570; 1a/: n 1419; 1b/: n 1120). b, MF bouton; s,
dendritic spine; d, dendritic shaft; asterisk, degenerated unmyelinated axon. Scale bars: 200
nm. Values are means SD.
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Figure1. Electronmicrographs showing thedistributionofGABAB1 immunogoldparticles at
MF-CA3 pyramidal neuron synapses in the stratum lucidum. A–C, In WT mice, immunogold
particles were predominantly detected on dendritic spines and shafts of pyramidal cells (ar-
rows) as well as in MF boutons (arrowheads). Immunogold particles were frequently found at
Figure 2. Distribution of GABAB1 immunogold particles in presynaptic and postsynaptic
elements of MF-CA3 pyramidal neuron synapses. A, Percentage of GABAB1 immunogold parti-
cles at presynaptic membrane specializations of MF boutons opposite to PSDs (WT: 22.5
3.9%; 1a/: 11.1 2.8%; 1b/: 22.2 0.8%, n 3, *p 0.05, ANOVA/Dunnett’s
multiple comparison post hoc test). B, Histogram showing the spatial distribution of dendritic
GABAB1 immunogold particles relative to the postsynaptic density. No significant differences
between genotypes were detected. GABAB1 immunogold particles were generally enriched in
the perisynaptic region within 60 nm from the edge of the PSD. Values are means SEM.
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Kir3-type K channels are not altered as a
consequence of the lack of GABAB1 iso-
form proteins. We tested whether lower
concentrations of baclofen possibly gener-
ate distinct K outward currents in 1a/
and 1b/ mice, which was not the case
(Fig. 4C). A reduction of K current am-
plitudes in 1a/ and 1b/ mice was
only observed at high concentrations of
baclofen (100 M), while at lower concen-
trations ( 10 M) the K current ampli-
tudes were similar in all genotypes (Fig.
4C). Since at all concentrations of baclofen
the GABAB-induced K
 currents in 1a/
and 1b/mice were similar, this suggests
that GABAB(1b,2) and GABAB(1a,2) recep-
tors are able to activate K channels to a
similar extent.
GABAB(1a,2) but not GABAB(1b,2)
receptors inhibit glutamate release in
response to physiological activation
To address to what extent the two GABAB
receptor subtypes contribute to physiolog-
ical inhibition of glutamate release at MF
terminals we examined heterosynaptic de-
pression in WT, 1a/, and 1b/ mice.
GABAB receptor-mediated heterosynaptic
depression of MF transmission has been
studied using fEPSP recordings and relies
on the activation of GABAB heterorecep-
tors by GABA released from neighboring
interneurons (Vogt and Nicoll, 1999;
Chandler et al., 2003). We first verified
that the stimulating electrode in the den-
tate gyrus evokes fEPSPs with properties
consistent with MF transmission. MF syn-
aptic responseswere identified by the pres-
ence of paired-pulse facilitation,
frequency-dependent short-term facilita-
tion and sensitivity to the mGluR agonist
DCG-IV, which blocks glutamate release
from the MF but not from the
associational-commissural fibers (Kamiya
et al., 1996; Yeckel et al., 1999; Kirschstein
et al., 2004; Nicoll and Schmitz, 2005).
When fEPSPs were evoked with paired-
pulse stimulation (100 ms apart), fEPSPs
exhibited a pronounced facilitation of
197.4 14.6% (n 16 slices). In addition,
when the stimulation frequency was in-
creased from 0.05 to 1 Hz, fEPSPs exhib-
ited a marked frequency-dependent facili-
tation of 246.3 26.3% (n 8 slices) (Fig.
5). Finally, as described (Kamiya et al.,
1996; Yeckel et al., 1999), bath application
ofDCG-IV reduced the amplitudeof fEPSPs
measured at 0.05 Hz to 38.9  5.5% (n  9 slices) (Fig. 5). Bath
applicationofCGP54626A(2M)hadnosignificant effecton fEPSP
peak amplitudes (control: 100 19.5%, n 7 slices; CGP54626A:
98.9  18.3%, n  7 slices), in keeping with patch-clamp experi-
ments showing that ambient levels ofGABAdonot tonically activate
GABAB heteroreceptors (Fig. 3D,E).
To induce heterosynaptic depression at MF synapses we
placed a second stimulating electrode into the dentate gyrus. The
position of this electrode and the stimulus intensitywere adjusted
such that two independent MF pathways could be stimulated
(Fig. 6A). Pathway one was stimulated at a regular interval of 10 s
to evoke MF test fEPSPs (S1). Every tenth stimulus was preceded
Figure 3. GABAB heteroreceptor function at MF-CA3 pyramidal neuron synapses. A, B, EPSC peak amplitudes plotted versus
time, average current traces, and summary histogramofmonosynaptic EPSCs inhibition bybaclofen (bac) and adenosine (adeno).
Baclofen (50M) depressed the amplitude of EPSCs to the same extent inWT and 1b/mice, but was less effective in 1a/
mice (WT: 78.6 2.6% inhibition, n 7; 1b/: 75.6 3.7% inhibition, n 6; 1a/: 36.4 7.3% inhibition, n 10,
***p 0.001, 1a/ compared with WT and 1b/, ANOVA/Scheffe post hoc test). The inhibitory effect of baclofen was
blocked by the GABAB receptor antagonist CGP54626A (CGP, 1M). As a control, adenosine (100M) efficiently reduced the peak
amplitudes of EPSCs in all genotypes (WT: 87.7 1.6% inhibition, n 6; 1a/: 80.4% 4.4% inhibition, n 8; 1b/:
85.72.2% inhibition,n4). Current traces inA showaverages of 10 successive EPSCs (calibration: 20ms/100pA).C, Inhibition
of glutamate release by different concentrations of baclofen. In 1a/ mice, baclofen was ineffective in inhibiting glutamate
release at 0.1M (n 5). At higher concentrations, baclofenwas always less effective in inhibiting glutamate release in 1a/
mice comparedwithWTor 1b/mice (1M, 1a/: 248.3% inhibition,n5, *p0.05, 1a/ comparedwithWTand
1b/; 50M, 1a/: 38.46.6% inhibition,n5, ***p0.001, 1a/ comparedwithWTand1b/, ANOVA/Scheffe
post hoc test). InWT and 1b/mice, baclofen reduced the peak amplitude of EPSCs to the same extent at 0.1M (WT: 26.5
3.4% inhibition, n 4; 1b/: 23.4 6.1% inhibition, n 4), 1M (WT: 57.2 5.6% inhibition, n 4; 1b/: 50.1
8.9% inhibition, n 4), and 50M (WT: 94.8 2.6% inhibition, n 4; 1b/: 94.2 2.2% inhibition, n 4). D, E, Lack of
evidence for a tonic activity of GABAB heteroreceptors at MF boutons.D, Evoked EPSCs of aWT CA3 pyramidal neuron recorded in
the absence and presence of CGP54626A (1M). E, Summary histogram showing that in all genotypes the peak amplitudes of
evoked EPSCs are not significantly altered in the presence of CGP54626A (WT: 98.2 4.5%, n 6; 1a/: 100.9 9.0%, n
6; 1b/: 102.8 6.1%, n 5). Values are means SEM.
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by a conditioning train of 20 stimuli at 100 Hz on pathway two
(S2). The two pathwayswere stimulated 200ms apart. To prevent
interference from presynaptic opioid and A1 adenosine recep-
tors, heterosynaptic depression was measured in the presence of
the antagonists naloxone and DPCPX. Under these conditions a
marked GABAB receptor-mediated heterosynaptic depression is
observed; only at strongerMF activation levels a direct activation
of presynaptic mGluRs through spillover of glutamate will occur
(Vogt and Nicoll, 1999). In WT mice, the amplitudes of test
fEPSPs evoked after a train on pathway two (conditioned fEPSPs,
closed circles) were significantly reduced by 25.7  3.3% ( p 
0.01,n 6 slices) comparedwith fEPSPsmeasured in the absence
of a conditioning train (unconditioned fEPSPs) (Fig. 6B,E, open
circles). CGP54626A largely or totally inhibited the reduction of
conditioned fEPSP amplitudes (Fig. 6B,E), confirming that het-
erosynaptic depression was mainly mediated by GABAB recep-
tors. NoGABAB-mediated heterosynaptic depressionwas detect-
able in 1a/mice (conditioned fEPSPs reduced by 2.5 1.4%,
p 0.20, n 6 slices) and accordingly, CGP54626A had no effect
on fEPSPs (Fig. 6C,E). In contrast, we observed a significant het-
erosynaptic depression in 1b/ mice (conditioned fEPSP am-
plitudes reduced by 26.2 2.8%, n 7 slices; p 0.001), which
was markedly reduced or abolished by CGP54626A (Fig. 6D,E).
Confirming that our recordings relate to MF transmission, fEP-
SPswere always inhibited by application ofDCG-IV (Fig. 6B–D).
Of note, the amplitudes of unconditioned fEPSPs in WT and
1b/ mice were increased in the presence of CGP54626A (Fig.
6B,D, open circles), suggesting that the GABA released by the
conditioning train lasts long enough to significantly inhibit un-
conditioned fEPSPs during the 90 s preceding the next condition-
ing train. In support of this, we found that CGP54626Awas with-
out effect on unconditioned fEPSP amplitudes in the absence of
the conditioning train (control: 100  18.6%, n  8 slices;
CGP54626A: 100.8  19.1%, n  8 slices). CGP54626A had no
Figure 4. GABAB-receptor-activated K
 currents in CA3 pyramidal neurons. A, B,
Changes in the holding current of CA3 pyramidal neurons following bath application of
baclofen (bac; 100 M) or adenosine (adeno; 100 M) and summary histogram of the
amplitude of baclofen- and adenosine-induced K currents. The baclofen-induced out-
ward K current was blocked by CGP54626A (CGP; 1 M) and significantly reduced in
1a/ and 1b/mice compared with WT mice (WT: 255.9 23.8 pA, n 6; 1a/:
112.8 17.5 pA, n 7; 1b/: 130.3 31.9 pA, n 7; *p 0.05, 1a/ and 1b/
compared with WT, ANOVA/Scheffe post hoc test). Control adenosine-induced K cur-
rents were similar in all genotypes (WT: 79.4 15.2 pA, n 6; 1a/: 57.1 12.7 pA,
n  7; 1b/: 64.0  16.5 pA, n  7), showing that effector K channels are not
altered in 1a/ and 1b/mice. C, Normalized K current amplitudes in response to
increasing concentrations of baclofen. The maximal K current amplitude for each con-
centration was normalized to the meanmaximal K current amplitude recorded fromWT
neurons at a saturating concentration of baclofen (100M). In 1a/ and 1b/mice,
the amplitude of baclofen-induced Kwas significantly reduced compared with WT mice
at 100 M (WT: 100 13.6%, n 5; 1a/: 63.7 7.7%, n 8; 1b/: 58.7
9.1%, n 5; *p 0.05, 1a/ and 1b/ compared with WT, ANOVA/Scheffe post hoc
test). Baclofen-induced K current amplitudes were not statistically different between
genotypes at concentrations of 0.3 M (WT: 3.6 0.9%, n 5; 1a/: 3.6 0.6%,
n 4; 1b/: 0.8 0.2%, n 4), 1M (WT: 7.4 2%, n 5; 1a/: 5.7 1.1%,
n  5; 1b/: 2.4  0.8%, n  4), and 10 M (WT: 21.7  3.5%, n  5; 1a/:
19.5 3.4%, n 6; 1b/: 15.5 2.9%, n 5). Values are means SEM.
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Figure 5. MF fEPSPs exhibit frequency-dependent short-term facilitation and sensitivity to
themGluR agonist DCG-IV. Average traces of fEPSPs recorded in the stratum lucidum at 0.05 Hz
and 1Hz and in the presence of DCG-IV (top) aswell as amplitudes of fEPSPs plotted versus time
(bottom) are shown. Increasing the stimulus frequency from 0.05 to 1 Hz induced pronounced
facilitation. Bath application of DCG-IV (2M) strongly inhibited fEPSP amplitudes elicited at
0.05 Hz.
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effect on unconditioned fEPSP amplitudes
in 1a/mice, in agreement with a lack of
functional GABAB heteroreceptors in
these mice (Fig. 6C). In summary, our ex-
periments show that exclusively
GABAB(1a,2) receptors mediate heterosyn-
aptic depression at MF-CA3 synapses.
Late IPSCs are detectable inWTmice
but not in 1a/ and 1b/mice
GABAB(1a,2) and GABAB(1b,2) receptors
produce K-currents of similar amplitude
in response to pharmacological activation
with baclofen (Fig. 4).However, it remains
possible that GABAB(1a,2) and GABAB(1b,2)
receptors produce distinct postsynaptic
responses following physiological activa-
tion, due to local differences in their soma-
todendritic abundance. In the hippocam-
pus, synaptically released GABA induces
Cl-dependent early IPSCs and K-
dependent late IPSCs that are mediated by
GABAA and GABAB receptors, respec-
tively (Misgeld et al., 1995; Lu¨scher et al.,
1997). We simultaneously recorded early
and late IPSCs in WT, 1a/, and 1b/
mice. The early IPSC allowed us to verify
that stimulation of the MF pathway pro-
voked GABA release in all of our record-
ings. The amplitude of the late IPSC was
used to quantify the extent of GABAB re-
ceptor activation in response to synapti-
cally released GABA. Three stimuli at 100
Hz reliably evoked early and late IPSCs in
WT mice. The occurrence of late IPSCs
was prevented in the presence of
CGP54626A, confirming that the late IP-
SCs are mediated by GABAB receptors
(Fig. 7A,D). No late IPSCs were detectable
in 1a/ and 1b/ mice, although early
IPSCs were always induced (Fig. 7B–D).
This suggests that the reduction of func-
tional postsynaptic GABAB receptors seen
in 1a/ and 1b/mice after pharmaco-
logical stimulation (Fig. 4) leads to sub-
threshold late IPSCs under physiological
conditions.
Figure 6. GABAB-mediated heterosynaptic depression at MF-CA3 pyramidal neuron synapses. A, Two electrodes (S1, S2)
positioned in the dentate gyrus were used to stimulate two independent pathways. A third electrode in the CA3 stratum lucidum
was used to record MF fEPSPs. Pathway 1 was stimulated at a regular interval of 10 s to evoke test fEPSPs (S1, unconditioned
response). Pathway 2was stimulated 200ms before every tenth test stimuluswith a train of 20 stimuli at 100 Hz (S2, conditioned
responses). B, GABAB-mediated heterosynaptic depression in slices of WT mice. The amplitudes of fEPSPs plotted over time
(bottom) and average traces (top) are shown. The amplitudes of fEPSPs preceded by a train (closed circles, red traces) were
reduced comparedwith those of fEPSPs not preceded by a train (open circles, black traces). Heterosynaptic depressionwas largely
inhibited or lost in the presence of CGP54626A (CGP; 2M). Average fEPSP traces are shown in the absence (1) and the presence
(2) of CGP54626A (stimulation artifacts were removed). C, GABAB-mediated heterosynaptic depression was absent in slices of
1a/ mice. The amplitudes of conditioned fEPSPs were similar to those of unconditioned fEPSPs. D, GABAB-mediated het-
erosynaptic depression in slices of 1b/micewas similar to that inWTmice and inhibited by CGP54626A. Note that CGP54626A
also increased the amplitude of unconditioned fEPSPs in WT and 1b/mice but not in 1a/mice (B–D). In all genotypes,
fEPSPs were inhibited by DCG-IV (2M). E, Summary histogram of GABAB-mediated heterosynaptic depression. The amplitudes
4
of conditioned fEPSPs were normalized to amplitudes of un-
conditioned fEPSPs in the absence (baseline) and presence of
CGP54626A. Significant CGP54626A-sensitive heterosynaptic
depression was observed in WT mice (baseline: 74.3 4%,
n 6 slices; CGP54626A: 100.8 2.7%, n 6 slices; **p
0.01, two-tailed paired Student’s t test) and 1b/ mice
(baseline: 73.8  2.8%, n  7 slices; CGP54626A: 95 
3.7%, n  7 slices; **p  0.01) but not in 1a/ mice
(baseline: 97.5 1.4%, n 6 slices; CGP54626A: 99.4
1.3%, n 6 slices; p 0.32). The ANOVA/Scheffe post hoc
test was used for the comparison of genotypes (***p 
0.001, normalized conditioned fEPSPs in 1a/ compared
with WT and 1b/mice). Values are means SEM.
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Discussion
GABAB(1a,2) andGABAB(1b,2) receptor subtypes exhibit compara-
ble pharmacological and functional properties when studied in
heterologous expression systems (Calver et al., 2002; Bettler et al.,
2004; Ulrich and Bettler, 2007). However, the two receptor sub-
types produce distinct responses at axonal and dendritic effectors
when pharmacologically activated by a saturating concentration
of baclofen (Pe´rez-Garci et al., 2006; Shaban et al., 2006; Vigot et
al., 2006; Ulrich and Bettler, 2007; Ulrich et al., 2007). Moreover,
the contributions of the two receptor subtypes to axonal or den-
dritic effector responses can vary in between neuronal popula-
tions. Two reasons probably account for neuron-specific differ-
ences in the responses of GABAB receptor subtypes. On the one
hand, GABAB1a and GABAB1b subunits are differentially distrib-
uted to axonal and dendritic compart-
ments (Vigot et al., 2006). On the other
hand, the expression of GABAB1a and
GABAB1b subunits is under separate tran-
scriptional control, which will influence
the ratio of receptor subtypes in individual
neurons (Steiger et al., 2004). It seems rea-
sonable to propose that separate control of
both transcription and distribution of
GABAB receptor subtypes has evolved to
provide neurons with ameans to indepen-
dently adjust signaling at select effector
systems. To support this concept, it is im-
portant to directly demonstrate that endo-
genously released GABA can differentially
activate GABAB receptor subtypes
(Huang, 2006). This is the case for inhibi-
tory synapses at cortical layer 5 pyramidal
neurons, where under physiological con-
ditions selectively GABAB(1a,2) and
GABAB(1b,2) receptors act as autoreceptors
and postsynaptic receptors, respectively
(Pe´rez-Garci et al., 2006). Here, we ad-
dressed whether this is also the case for
GABAB heteroreceptors at glutamatergic
synapses. A physiological phenomenon
that is reported to depend on the endoge-
nous activation of GABAB heteroreceptors
is heterosynaptic depression (Isaacson et
al., 1993; Vogt and Nicoll, 1999; Chandler
et al., 2003). We therefore determined the
individual contributions of the two
GABAB receptor subtypes to heterosynap-
tic depression at MF-CA3 pyramidal neu-
ron synapses, where this phenomenon can
be easily studied (Vogt and Nicoll, 1999;
Chandler et al., 2003). Our data show that
exclusively GABAB(1a,2) heteroreceptors
mediate heterosynaptic depression of MF
transmission. Yet the presence of func-
tional GABAB(1b,2) heteroreceptors at MF
boutons can be demonstrated in pharma-
cological experiments, in which concen-
trations of baclofen 1 M produce a
component of presynaptic inhibition me-
diated by GABAB(1b,2) receptors. In phar-
macological experiments, a selective pre-
synaptic inhibition via GABAB(1a,2)
heteroreceptors was only observed at a
lower concentration of baclofen (0.1 M). The most parsimoni-
ous explanation for these data is that the number of GABAB(1b,2)
receptors at presynaptic sites in 1a/mice is sufficient to mea-
surably inhibit glutamate release in response to pharmacological
activation with moderate to high concentrations of baclofen, but
not to inhibit release in response to low concentrations of spill-
over GABA from neighboring interneurons. This may be accen-
tuated by the fact that presynaptic GABAB receptors at MF bou-
tons display non-desensitizing properties (Tosetti et al., 2004),
which will render sustained pharmacological inhibition particu-
larly effective. Baclofen likely also activates somatic GABAB(1b,2)
receptors in the dentate granule cells. The ensuing hyperpolariz-
ing potentials may passively propagate to the MF boutons and
contribute to presynaptic inhibition (Alle and Geiger, 2006). The
Figure 7. GABAA-mediated early IPSCs and GABAB-mediated late IPSCs recorded from CA3 pyramidal neurons in acute hip-
pocampal slices. A–C, Average traces of early and late IPSCs recorded from WT, 1a/, and 1b/ brain slices (black traces).
IPSCs were recorded at a holding potential of60mV and an internal Cl concentration of 20mM, which yields inward currents
for early IPSCs and outward currents for late IPSCs. Application of CGP54626A (2M) abolished late IPSCs without affecting early
IPSCs (red traces).D, Mean peak amplitudes of the first early IPSC (GABAA, left) and the late IPSC (GABAB, right). Early IPSCs were
of similar amplitudes in all three genotypes (WT: 104.5 18.5 pA, n 9; 1a/: 128.6 23.4 pA, n 9; 1b/: 140.3
38.4 pA, n 5; p	 0.05). Late IPSCs were only detectable inWTmice (6.9 0.8 pA, n 9) but not in 1a/mice (n 9) or
1b/mice (n 5). Currents were recorded in the presence of kynurenic acid (2 mM), DNQX (10M), naloxone (10M), and
DPCPX (1M). Values are means SEM.
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exact reason for presynaptic inhibition following pharmacologi-
cal activation with baclofen is unknown. However, our results
support that the spatial segregation of GABAB1 isoforms at MF
terminals is sufficient to produce a strictly subtype-specific het-
eroreceptor response under physiological conditions. At other
glutamatergic synapses baclofen also produces a significant level
of presynaptic inhibition through GABAB(1b,2) heteroreceptors
(Shaban et al., 2006; Vigot et al., 2006; Ulrich et al., 2007). We
expect that under physiological conditions exclusively
GABAB(1a,2) receptors mediate heteroreceptor function at those
synapses as well.
Heterosynaptic depression at MF-CA3 pyramidal neuron
synapses is thought to play an important role in regulating mne-
monic processes (Jin and Chavkin, 1999; Vogt and Nicoll, 1999;
Vida and Frotscher, 2000; Chandler et al., 2003). Heterosynaptic
depression increases the sparseness of input signals to CA3 pyra-
midal cells, thereby enhancing the storage capacity of the CA3
network. Overt memory deficits in hippocampus-dependent
memory tasks in 1a/ mice (Vigot et al., 2006; Jacobson et al.,
2007) may therefore relate, at least in part, to the disinhibition of
MF inputs and the ensuing failure to store or recall memory
traces. In addition, the control of GABAB1a-mediated inhibition
at MF boutons may be important for regulating synaptic plastic-
ity and limbic seizure prevention, since these processes were also
shown to be controlled by GABAB heteroreceptors (Vogt and
Nicoll, 1999; Chandler et al., 2003).
We found that baclofen induces similar maximal K currents
in CA3 neurons of 1a/ and 1b/ mice. Given the surplus of
GABAB1b protein at dendritic sites opposite to MF terminals, it
may appear surprising that the maximal K currents induced by
GABAB(1b,2) receptors are not larger than those induced by
GABAB(1a,2) receptors. However, caution should be exerted when
comparing the ultrastructural data with the electrophysiological
data. On the one hand, the GABAB receptors included in the
ultrastructural analysis may not necessarily be coupled to K
channels. For example, it is conceivable that a larger fraction of
GABAB(1a,2) receptors is colocalized with Kir3-type K
 channels,
rendering their coupling to effector channelsmore efficient (Kar-
schin, 1999). Future studies, for example using high-resolution
immunocytochemical techniques (Kulik et al., 2006), will have to
address whether GABAB1 isoforms exhibit differences in the co-
localization with Kir3-type K channel subunits. On the other
hand, baclofen probably mostly activates K currents via soma-
todendritic GABAB receptors remote from MF synapses, and
these receptors were excluded from the ultrastructural analysis. It
is possible that the relative abundance of GABAB(1a,2) and
GABAB(1b,2) receptors differs between dendritic spines and shafts,
similar as observed in CA1 pyramidal neurons where GABAB1a
protein does not efficiently enter the spines (Vigot et al., 2006). It
further could be argued that the downregulation of GABAB1a
protein levels during early postnatal development (Malitschek et
al., 1998; Fritschy et al., 1999) accounts for the difference between
the morphological and electrophysiological data. However, rul-
ing out this possibility, all our experiments were performed with
mice 3 weeks of age or older, when GABAB1a and GABAB1b pro-
tein levels remain stable (Malitschek et al., 1998). While many
factors can contribute to the difference between the ultrastruc-
tural data of spines and the electrophysiological responses re-
corded for the soma of CA3 pyramidal neurons, our data further
consolidate that the relative contributions of GABAB1a and
GABAB1b subunits to the pool of GABAB receptors coupled to
effector K channels varies in between neurons (Ulrich and Bet-
tler, 2007). Importantly, a physiological activation of somatoden-
dritic GABAB receptors by synaptically released GABA does not
produce a segregation of GABAB(1a,2) and GABAB(1b,2) responses
in CA3 pyramidal neurons, in contrast to the findings with cor-
tical neurons (Huang, 2006; Pe´rez-Garci et al., 2006).
In conclusion, our results are consistentwith the proposal that
independent regulation of expression and distribution of GABAB
receptor subtypes enables neurons to dynamically adjust GABAB
signaling at axonal and dendritic effectors. The observation that
GABAB1a and GABAB1b cannot compensate for each other in
response to synaptically releasedGABA is important fromaphar-
maceutical perspective. The existence of two functionally distinct
GABAB receptor subtypes enables a more selective interference
with the GABAB receptor system, which may be of therapeutic
benefit for the treatment of neurological and psychiatric disor-
ders (Tiao et al., 2008).
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